ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 133 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 1.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $73,000 | +58.7% | 3,877 | 0.0% | 0.00% | – |
| Q2 2019 | $46,000 | -13.2% | 3,877 | 0.0% | 0.00% | – |
| Q1 2019 | $53,000 | +39.5% | 3,877 | +4.7% | 0.00% | – |
| Q4 2018 | $38,000 | -38.7% | 3,702 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $62,000 | +29.2% | 3,702 | +20.7% | 0.00% | – |
| Q2 2018 | $48,000 | +23.1% | 3,066 | 0.0% | 0.00% | – |
| Q1 2018 | $39,000 | +11.4% | 3,066 | 0.0% | 0.00% | – |
| Q4 2017 | $35,000 | +169.2% | 3,066 | +198.2% | 0.00% | – |
| Q3 2017 | $13,000 | +8.3% | 1,028 | 0.0% | 0.00% | – |
| Q2 2017 | $12,000 | -42.9% | 1,028 | 0.0% | 0.00% | – |
| Q1 2017 | $21,000 | 0.0% | 1,028 | 0.0% | 0.00% | – |
| Q4 2016 | $21,000 | -38.2% | 1,028 | 0.0% | 0.00% | – |
| Q3 2016 | $34,000 | +61.9% | 1,028 | +23.7% | 0.00% | – |
| Q2 2016 | $21,000 | +5.0% | 831 | 0.0% | 0.00% | – |
| Q1 2016 | $20,000 | -25.9% | 831 | 0.0% | 0.00% | – |
| Q4 2015 | $27,000 | +237.5% | 831 | +235.1% | 0.00% | – |
| Q3 2015 | $8,000 | – | 248 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 2,942,130 | $40,160,000 | 10.45% |
| Foresite Capital Management II, LLC | 1,586,220 | $21,652,000 | 9.78% |
| DAFNA Capital Management LLC | 571,013 | $7,794,000 | 3.36% |
| Redmile Group, LLC | 8,244,896 | $112,543,000 | 3.29% |
| Lion Point Capital, LP | 1,271,500 | $17,355,000 | 1.57% |
| Palo Alto Investors LP | 1,861,630 | $25,411,000 | 1.06% |
| SAMLYN CAPITAL, LLC | 3,185,983 | $43,488,000 | 1.03% |
| Bellevue Group AG | 1,286,748 | $17,564,000 | 0.97% |
| BB BIOTECH AG | 2,766,008 | $37,756,000 | 0.95% |
| Rock Springs Capital Management LP | 1,560,000 | $21,294,000 | 0.82% |